A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
Public ClinicalTrials.gov record NCT00754988. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This 4 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin. Patients will be randomized to receive taspoglutide (10mg once weekly or 10mg once weekly for 4 weeks followed by 20mg once weekly), sitagliptin 100mg once daily or placebo, in a ratio of 2:2:2:1, in addition to their continued prestudy metformin treatment. After 24 weeks of treatment, patients on active treatment will continue on the same treatment and patients on placebo will be switched to taspoglutide 10mg once weekly or taspoglutide 20mg once weekly (after 4 weeks of taspoglutide 10mg once weekly). The anticipated time on study treatment is 2+ years, and the target sample size is 500+ individuals.
Study identification
- NCT ID
- NCT00754988
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 666 participants
Conditions and interventions
Conditions
Interventions
- Metformin Drug
- Placebo (matching sitagliptin) Drug
- Placebo (matching taspoglutide) Drug
- Sitagliptin Drug
- Taspoglutide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2008 (Type not available)
- Primary completion
- Mar 2011 (Actual)
- Completion
- Mar 2011 (Actual)
- Last update posted
- Nov 4, 2016
2008 – 2011
United States locations
- U.S. sites
- 64
- U.S. states
- 27
- U.S. cities
- 61
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35233 | — |
| Not listed | Huntsville | Alabama | 35802 | — |
| Not listed | Tallassee | Alabama | 36078 | — |
| Not listed | Scottsdale | Arizona | 85254 | — |
| Not listed | Little Rock | Arkansas | 72205 | — |
| Not listed | Huntington Beach | California | 92646 | — |
| Not listed | La Jolla | California | 92037 | — |
| Not listed | Los Angeles | California | 90017 | — |
| Not listed | Roseville | California | 95661 | — |
| Not listed | San Francisco | California | 94109 | — |
| Not listed | Tacoma | California | 98405 | — |
| Not listed | Colorado Springs | Colorado | 80904 | — |
| Not listed | New London | Connecticut | 06320 | — |
| Not listed | Manati | District of Columbia | 00674 | — |
| Not listed | Daytona Beach | Florida | 32117 | — |
| Not listed | Hialeah | Florida | 33012 | — |
| Not listed | Jacksonville | Florida | 32205 | — |
| Not listed | Miami | Florida | 33186 | — |
| Not listed | Panama City | Florida | 32401 | — |
| Not listed | Tampa | Florida | 33606 | — |
| Not listed | Augusta | Georgia | 30904 | — |
| Not listed | Conyers | Georgia | 30094 | — |
| Not listed | Snellville | Georgia | 30029 | — |
| Not listed | Honolulu | Hawaii | 96813 | — |
| Not listed | Indianapolis | Indiana | 46229 | — |
| Not listed | Indianapolis | Indiana | 46254 | — |
| Not listed | Lafayette | Indiana | 47905 | — |
| Not listed | South Bend | Indiana | 46628 | — |
| Not listed | Baltimore | Maryland | 21229 | — |
| Not listed | Brockton | Massachusetts | 02301 | — |
| Not listed | Cadillac | Michigan | 49601 | — |
| Not listed | Brooklyn Center | Minnesota | 55430 | — |
| Not listed | Minneapolis | Minnesota | 55416 | — |
| Not listed | City of Saint Peters | Missouri | 63376 | — |
| Not listed | Fulton | New York | 13069 | — |
| Not listed | Hudson | New York | 12534 | — |
| Not listed | Rochester | New York | 14609 | — |
| Not listed | Charlotte | North Carolina | 28211 | — |
| Not listed | Raleigh | North Carolina | 27609 | — |
| Not listed | Shelby | North Carolina | 28150 | — |
| Not listed | Statesville | North Carolina | 28625 | — |
| Not listed | Winston-Salem | North Carolina | 27103 | — |
| Not listed | Columbus | Ohio | 43213 | — |
| Not listed | Delaware | Ohio | 43015 | — |
| Not listed | Marion | Ohio | 43302 | — |
| Not listed | Corvallis | Oregon | 97330 | — |
| Not listed | Eugene | Oregon | 97401 | — |
| Not listed | Aliquippa | Pennsylvania | 15001 | — |
| Not listed | Beaver | Pennsylvania | 15009 | — |
| Not listed | Erie | Pennsylvania | 16508 | — |
| Not listed | Reading | Pennsylvania | 17601 | — |
| Not listed | Reading | Pennsylvania | 19606 | — |
| Not listed | Shippensburg | Pennsylvania | 17257 | — |
| Not listed | Warminster | Pennsylvania | 18974 | — |
| Not listed | Anderson | South Carolina | 29621 | — |
| Not listed | Kingsport | Tennessee | 37660 | — |
| Not listed | Dallas | Texas | 75230 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | South Burlington | Vermont | 05403 | — |
| Not listed | Hampton | Virginia | 23666 | — |
| Not listed | Norfolk | Virginia | 23502 | — |
| Not listed | Richmond | Virginia | 23249 | — |
| Not listed | Richmond | Virginia | 23294 | — |
| Not listed | Federal Way | Washington | 98003 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 84 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00754988, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2016 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00754988 live on ClinicalTrials.gov.